Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4044 Comments
1269 Likes
1
Aliaa
Insight Reader
2 hours ago
Hard work really pays off, and it shows.
π 215
Reply
2
Anyce
Expert Member
5 hours ago
Who else is following this closely?
π 188
Reply
3
Zahra
Regular Reader
1 day ago
So disappointed I missed it. π
π 245
Reply
4
Macauley
Active Reader
1 day ago
I read this and now Iβm thinking too much.
π 99
Reply
5
Sanura
Power User
2 days ago
This feels like something important is missing.
π 147
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.